Beardsworth(R) Selects OmniComm Systems' TrialMaster(TM) Solution for the Electronic Data Capture (EDC) of a Phase II Vaccine St

Beardsworth(R) Selects OmniComm Systems' TrialMaster(TM) Solution for the Electronic Data Capture (EDC) of a Phase II Vaccine Study

OmniComm Systems, Inc. (OTCBB: OMCM), one of the fastest growing companies in the EDC marketplace, today announced that Beardsworth, a full service contract research organization (CRO) who specializes in difficult therapeutic areas, has selected OmniComm's TrialMaster EDC solution for conducting a Phase II vaccine study. The 3-year, 10-site study is planning to enroll 340 subjects. "After a careful selection process, we chose OmniComm Systems to be our preferred EDC provider," said Michael J. O'Brien, Beardsworth President and CEO. "OmniComm's solid reputation, early adoption of industry standards, and the many features and benefits the platform offers, made it a logical choice."

OmniComm and Beardsworth plan electronic imports of data to TrialMaster EDC utilizing OmniComm's native, template matching, subsystem. Electronic exports from TrialMaster EDC to Beardsworth's BNet portal will be achieved utilizing OmniComm's new RESTful Web Services, Application Programming Interface (API). This API technology, developed using a RESTful Web Services architecture, leverages CDISC standards and allows for easy integration with external data sources like BNet.

"We look forward to working with Beardsworth on their next study and welcome them to our very successful CRO preferred program," remarked Stephen Johnson, COO of OmniComm Systems. "We are pleased that OmniComm's electronic data capture solution, TrialMaster, was chosen to capture and process the clinical trial data of this exciting vaccine study. TrialMaster will enable Beardsworth to confidently offer their clients an extensible, eClinical solution that will complement the outstanding services which have made their company a success."

About Beardsworth

Beardsworth Consulting Group, Inc. ( is a full-service CRO whose service offerings span all stages of drug development and clinical trial management. With a command of the complex trial, Beardsworth's niche expertise focuses on oncology/supportive care and vaccine/anti-infective therapeutics. In business since 1986, Beardsworth brings 20+ years of experience, expertise and commitment to provide solution-based business models for results on time and within budget. A woman-owned business, Beardsworth is proud to be WBENC-certified. Headquartered in Flemington, New Jersey, Beardsworth's network of medical monitors and strategic alliances crisscross the globe.

About OmniComm

OmniComm Systems, Inc. ( provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small, to large-scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.

Safe Harbor Disclaimer

Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.